Biomarker Analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 33, 2014, Pages 3753-3761

  Baselga, José ^a   Cortés, Javier ^b   Im, Seock Ah ^c   Clark, Emma ^d   Ross, Graham ^d   Kiermaier, Astrid ^e   Swain, Sandra M ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Seoul National University College of Medicine   (South Korea)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETACELLULIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GENE MUTATION; HUMAN; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; FEMALE; GENETICS; METASTASIS; MORTALITY; MUTATION; PROGNOSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84911926434     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.5384     Document Type: Article

References (22)

1. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
2. Swain S, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
3. Barok M, Isola J, Pályi-Krekk Z, et al: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6:2065-2072, 2007
4. Molina MA, Codony-Servat J, Albanell J, et al: Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-4749, 2001
5. Junttila TT, Akita RW, Parsons K, et al: Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
6. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
7. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
8. Scheuer W, Friess T, Burtscher H, et al: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330-9936, 2009
9. Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343-2346, 2004
10. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
11. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003
12. Schneeweiss A, Chia S, Hegg R, et al: Biomarker (BM) analyses of a phase II study of neoadjuvant pertuzumab and trastuzumab with and without anthracycline (ATC)-containing chemotherapy for treatment of HER2-positive early breast cancer (BC) (TRYPHAENA). Ann Oncol 23, 2012 (suppl 9; abstr 202P)
13. Gianni L, Bianchini G, Kiermaier A, et al: Neoadjuvant pertuzumab (P) and trastuzumab (H): Biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 7, 2011 (suppl 24; abstr S5-1)
14. Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230, 2008
15. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007
16. Cizkova M, Susini A, Vacher S, et al: PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res 14:R28, 2012
17. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107:10208-10213, 2012
18. Kalinsky K, Jacks LM, Heguy A, et al: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049-5059, 2009
19. Isakoff SJ, Engelman JA, Irie HY, et al: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65:10992-11000, 2005
20. Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
21. Juric D, Krop I, Ramanathan RK, et al: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Presented at the American Association for Cancer Researc Annual Meeting, Washington DC, April 6-10, 2013 (abstr LB-64)
22. Phillips GD, Fields CT, Li G, et al: Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20:456-468, 2014